Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod
By Takashi Ebisawa After a major setback in an I/O combo trial last year, AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) notched up approval as a single-agent maintenance treatment for a previously untapped pool of Stage III lung cancer patients. Japan…
To read the full story
Related Article
- I/O in Lung Cancer - 7: Oncologist Sees Promise in I/O-I/O Combos, Prods Quest for Cure
October 5, 2018
- I/O in Lung Cancer - 6: Analyst Says US Merck Claimed Victory in 2018 ASCO Confab, Applauds Trial Designs for Keytruda
September 26, 2018
- I/O in Lung Cancer - 5: Roche Looks Beyond Tecentriq, Laying Foundation for Next-Gen Immunotherapies
September 13, 2018
- I/O in Lung Cancer - 4: Bristol-Myers Looks to Regain Ground for Opdivo with Immunotherapy Combos
September 5, 2018
- I/O in Lung Cancer - 3: Pfizer Sets Sights on Ovarian Cancer after NSCLC Trial Fails
August 28, 2018
- I/O in Lung Cancer - 1: US Merck Sweeping Frontline NSCLC Space with Keytruda
August 10, 2018
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…